Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study [PDF]
Acta OncologicaBackground: The role and optimal sequencing of radium-223 in the treatment of metastatic castration-resistant prostate cancer (mCRPC) remain debated.
Charlotte Alverbratt +5 more
doaj +2 more sources
Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment [PDF]
Diagnostics, 2023 (1) Background: Prostate cancer is the second most common cancer in men, with androgen suppression as the standard treatment. Despite initially responding to castration, most metastatic prostate cancer patients eventually experience progression. In these
Elisabet Cantó +7 more
doaj +2 more sources
Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study [PDF]
Oncology and TherapyIntroduction Radium-223 is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, without visceral metastases, who progress after at least (≥) two lines of or are ineligible for other systemic ...
Rachel Weinrib +12 more
doaj +2 more sources
Ocular complications with the use of radium-223: a case series [PDF]
Radiation Oncology, 2022 Background Radium-223 is used for the treatment of osseous metastases in castrate-resistant prostate cancer, and has been shown to increase time to the first skeletal-related event, reduce the rate of hospitalization, and improve quality of life.
Julie R. Bloom +5 more
doaj +2 more sources
Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer [PDF]
Current OncologyIntroduction: Radium-223 dichloride (radium-223) is a bone-targeting radioisotope therapy that aids in the survival of patients with metastatic castration-resistant prostate cancer (mCRPC) to bones.
Colleen Mackenzie +9 more
doaj +2 more sources
Bilateral neovascular glaucoma associated with Radium-223 infusions for prostate cancer [PDF]
American Journal of Ophthalmology Case ReportsPurpose: To report two cases of neovascular glaucoma associated with Radium-223 infusion. Observations: Presented are two patients with metastatic prostate cancer who developed uncontrolled intraocular pressure secondary to neovascular glaucoma requiring
Chelsea M. Viscardi +2 more
doaj +2 more sources
The Tight Relationship Between the Tumoral Microenvironment and Radium-223 [PDF]
BiomedicinesRadium-223 (223Ra) was the first radioactive isotope approved for treating castration-resistant prostate cancer (CRPC) with symptomatic bone metastases without visceral metastatic disease.
Miriam Conte +7 more
doaj +2 more sources
Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies [PDF]
DiagnosticsRecent advances have broadened the range of therapeutic options for mCRPC, with several new treatments, including novel hormonal therapies (enzalutamide, abiraterone), chemotherapeutic agents (docetaxel, cabazitaxel), immunotherapies (sipuleucel-T), and ...
Ali H. D. Alshehri
doaj +2 more sources
EClinicalMedicine, 2023 Summary: Background: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in ...
Celestia S. Higano +14 more
doaj +1 more source
Frontiers in Oncology, 2022 Radium-223 is commonly used in metastatic prostate cancer, targeting specifically bone metastases. The use of radium-223 remains, however, poorly evaluated in metastatic breast cancer.
Hélène Houssiau +3 more
doaj +1 more source